Atrion (ATRI) 10-K 14 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 12, 2014	Jun. 30, 2013
Document Information	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'ATRI	'	'
Entity Registrant Name	'ATRION CORP	'	'
Entity Central Index Key	'0000701288	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	1,984,605	'
Entity Public Float	'	'	$345,521,557

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues	$131,993	$119,062	$117,704
Cost of Goods Sold	68,931	62,922	57,697
Gross Profit	63,062	56,140	60,007
Operating Expenses:	'	'	'
Selling	6,218	5,694	5,325
General and administrative	14,612	13,054	13,646
Research and development	4,288	3,766	2,868
Operating Expenses, Total	25,118	22,514	21,839
Operating Income	37,944	33,626	38,168
Interest Income	1,313	1,447	1,295
Other Income, net	8	2	12
Income before Provision for Income Taxes	39,265	35,075	39,475
Provision for Income Taxes	-12,683	-11,446	-13,437
Net Income	$26,582	$23,629	$26,038
Net Income Per Basic Share	$13.22	$11.72	$12.90
Weighted Average Basic Shares Outstanding	2,010	2,016	2,019
Net Income Per Diluted Share	$13.18	$11.66	$12.82
Weighted Average Diluted Shares Outstanding	2,017	2,027	2,031
Dividends Per Common Share	$2.40	$12.10	$1.82

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$28,559	$7,999
Short-term investments	18,351	8,182
Accounts receivable, net of allowance for doubtful accounts of $86 and $47 in 2013 and 2012, respectively	14,164	13,054
Inventories	26,266	23,779
Prepaid expenses and other current assets	1,603	3,110
Deferred income taxes	1,376	623
Total Current Assets	90,319	56,747
Long-term investments	10,069	28,433
Property, Plant and Equipment	130,504	124,180
Less accumulated depreciation and amortization	72,176	64,912
Property plant and equipment net	58,328	59,268
Other Assets and Deferred Charges:	'	'
Patents and licenses, net of accumulated amortization of $11,032 and $10,853 in 2013 and 2012, respectively	2,808	837
Goodwill	9,730	9,730
Other	812	795
Prepaid Expense and Other Assets, Noncurrent, Total	13,350	11,362
Total Assets	172,066	155,810
Current Liabilities:	'	'
Accounts payable	4,088	3,843
Accrued liabilities	4,423	2,900
Accrued income and other taxes	853	465
Total Current Liabilities	9,364	7,208
Line of credit	'	'
Other Liabilities and Deferred Credits:	'	'
Deferred income taxes	12,062	12,232
Other	1,646	1,542
Liabilities Noncurrent	13,708	13,774
Total Liabilities	23,072	20,982
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Common stock, par value $.10 per share, authorized 10,000 shares, issued 3,420 shares	342	342
Additional paid-in capital	31,592	29,998
Retained earnings	174,362	152,630
Treasury shares, 1,428 shares in 2013 and 1,399 shares in 2012, at cost	-57,302	-48,142
Total Stockholders' Equity	148,994	134,828
Total Liabilities and Stockholders' Equity	$172,066	$155,810

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Accounts receivable, allowance for doubtful accounts	$86	$47
Patents and licenses, accumulated amortization	$11,032	$10,853
Common stock, par value	$0.10	$0.10
Common stock, authorized	10,000	10,000
Common stock, issued	3,420	3,420
Treasury shares, shares	1,428	1,399

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash Flows From Operating Activities:	'	'	'
Net Income	$26,582	$23,629	$26,038
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	8,592	7,610	6,544
Deferred income taxes	-923	1,462	2,584
Stock-based compensation	1,586	1,482	1,047
Net change in accrued interest, premiums, and discounts on investments	556	817	824
Other	30	'	'
Net Cash Provided By Used In Operating Activities Before Changes In Operating Capital, Total	36,423	35,000	37,037
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-1,110	-1,831	298
Inventories	-2,487	803	-7,182
Prepaid expenses and other current assets	1,507	-797	-1,263
Other non-current assets	-17	-77	18
Accounts payable and accrued liabilities	1,768	-2,465	2,008
Accrued income and other taxes	388	-370	283
Other non-current liabilities	104	-894	341
Net Cash Provided by (Used in) Operating Activities, Total	36,576	29,369	31,540
Cash Flows From Investing Activities:	'	'	'
Property, plant and equipment additions	-7,503	-10,347	-11,999
Purchase of patents	-2,150	'	'
Purchase of investments	'	-26,566	-14,723
Proceeds from maturities of investments	7,639	19,750	14,290
Net Cash Provided by (Used in) Investing Activities, Total	-2,014	-17,163	-12,432
Cash Flows From Financing Activities:	'	'	'
Exercise of stock options	'	731	'
Shares tendered for employees' withholding taxes on stock-based compensation	'	-1,136	-78
Tax benefit related to stock-based compensation	15	1,412	79
Purchase of treasury stock	-9,196	-5,344	-1,513
Dividends paid	-4,821	-24,460	-3,676
Net Cash Provided by (Used in) Financing Activities, Total	-14,002	-28,797	-5,188
Net change in cash and cash equivalents	20,560	-16,591	13,920
Cash and cash equivalents, beginning of year	7,999	24,590	10,670
Cash and cash equivalents, end of year	28,559	7,999	24,590
Cash paid for:	'	'	'
Income taxes	$8,036	$10,357	$11,921

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Stockholders' Equity (USD $)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings
In Thousands
Beginning Balances at Dec. 31, 2010	$116,617	$342	($39,342)	$24,331	$131,286
Beginning Balances (in shares) at Dec. 31, 2010	'	2,016	1,404	'	'
Net Income	26,038	'	'	'	26,038
Tax benefit from stock-based compensation	79	'	'	79	'
Stock-based compensation transactions (in shares)	'	8	-8	'	'
Stock-based compensation transactions	1,077	'	35	1,042	'
Shares surrendered in stock transactions	-78	'	-78	'	'
Purchase of treasury stock (in shares)	'	-8	8	'	'
Purchase of treasury stock	-1,513	'	-1,513	'	'
Dividends	-3,706	'	'	'	-3,706
Ending Balances at Dec. 31, 2011	138,514	342	-40,898	25,452	153,618
Ending Balances (in shares) at Dec. 31, 2011	'	2,016	1,404	'	'
Net Income	23,629	'	'	'	23,629
Tax benefit from stock-based compensation	1,412	'	'	1,412	'
Stock-based compensation transactions (in shares)	'	41	-41	'	'
Stock-based compensation transactions	3,502	'	368	3,134	'
Shares surrendered in stock transactions (in shares)	'	-9	9	'	'
Shares surrendered in stock transactions	-2,268	'	-2,268	'	'
Purchase of treasury stock (in shares)	'	-27	27	'	'
Purchase of treasury stock	-5,344	'	-5,344	'	'
Dividends	-24,617	'	'	'	-24,617
Ending Balances at Dec. 31, 2012	134,828	342	-48,142	29,998	152,630
Ending Balances (in shares) at Dec. 31, 2012	'	2,021	1,399	'	'
Net Income	26,582	'	'	'	26,582
Tax benefit from stock-based compensation	15	'	'	15	'
Stock-based compensation transactions (in shares)	'	1	-1	'	'
Stock-based compensation transactions	1,615	'	36	1,579	'
Purchase of treasury stock (in shares)	'	-30	30	'	'
Purchase of treasury stock	-9,196	'	-9,196	'	'
Dividends	-4,850	'	'	'	-4,850
Ending Balances at Dec. 31, 2013	$148,994	$342	($57,302)	$31,592	$174,362
Ending Balances (in shares) at Dec. 31, 2013	'	1,992	1,428	'	'

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
	(1) Summary of Significant Accounting Policies
	Atrion Corporation and its subsidiaries (“we,” “our,” “us,” “Atrion” or the “Company”) develop and manufacture products primarily for medical applications. We market our products throughout the United States and internationally.  Our customers include hospitals, distributors, and other manufacturers.  Atrion Corporation’s principal subsidiaries through which these operations are conducted are Atrion Medical Products, Inc., Halkey-Roberts Corporation and Quest Medical, Inc.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Atrion Corporation and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	Cash equivalents include cash on hand and in the bank as well as money market accounts and debt securities with original maturities of 90 days or less.
	Trade Receivables
	Trade accounts receivable are recorded at the original sales price to the customer.  We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments.  On an ongoing basis, the collectability of accounts receivable is assessed based upon historical collection trends, current economic factors and the assessment of the collectability of specific accounts.  We evaluate the collectability of specific accounts and determine when to grant credit to our customers using a combination of factors, including the age of the outstanding balances, evaluation of customers’ current and past financial condition, recent payment history, current economic environment, and discussions with appropriate Company personnel and with the customers directly.  Accounts are written off when we determine the receivable will not be collected.
	Investments
	Our investments consist of taxable corporate bonds. Our investment policy is to seek to preserve principal and maintain adequate liquidity while at the same time maximizing yields without significantly increasing risk. We are required to classify our investments as trading, available-for-sale or held-to-maturity. Our investments are accounted for as held-to-maturity since we have the positive intent and ability to hold these investments to maturity. These investments are reported at cost, adjusted for premiums and discounts that are recognized in interest income, using a method that approximates the effective interest method, over the period to maturity and unrealized gains and losses are excluded from earnings. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets.
	Inventories
	Inventories are stated at the lower of cost (including materials, direct labor and applicable overhead) or market. Cost is determined by using the first-in, first-out method. The following table details the major components of inventory (in thousands):
		December 31,
		2013		2012
	Raw materials	$	10,744	$	10,017
	Work in process		6,246		5,268
	Finished goods		9,276		8,494
	Total inventories	$	26,266	$	23,779
	Accounts Payable
	We reflect disbursements as trade accounts payable until such time as payments are presented to our bank for payment. At December 31, 2013 and 2012, disbursements totaling approximately $443,000 and $495,000, respectively, had not been presented for payment to our bank.
	Income Taxes
	We account for income taxes utilizing Accounting Standards Codification (ASC) 740, Income Taxes (“ASC 740”).  ASC 740 requires the asset and liability method for the recording of deferred income taxes, whereby deferred tax assets and liabilities are recognized based on the tax effects of temporary differences between the financial statement and the tax bases of assets and liabilities, as measured at current enacted tax rates. When appropriate, we evaluate the need for a valuation allowance to reduce deferred tax assets.
	ASC 740 also requires the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attributes of income tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more-likely-than-not of being sustained.
	Our uncertain tax positions are recorded as “Other non-current liabilities.” We classify interest expense on underpayments of income taxes and accrued penalties related to unrecognized tax benefits in the income tax provision.
	Property, Plant and Equipment
	Property, plant and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Additions and improvements are capitalized, including all material, labor and engineering costs to design, install or improve the asset. Expenditures for repairs and maintenance are charged to expense as incurred. The following table represents a summary of property, plant and equipment at original cost (in thousands):
		December 31,				Useful
		2013		2012		Lives
	Land	$	5,260	$	5,260	—
	Buildings		31,314		30,664	30-40 yrs
	Machinery and equipment		93,930		88,256	3-15 yrs
	Total property, plant and equipment	$	130,504	$	124,180
	Depreciation expense of $8,413,000, $7,448,000 and $6,272,000 was recorded for the years ended December 31, 2013, 2012 and 2011, respectively. Depreciation expense is recorded in either cost of goods sold or operating expenses based on the associated assets’ usage.
	Patents and Licenses
	Costs for patents and licenses acquired are determined at acquisition date. Patents and licenses are amortized over the useful lives of the individual patents and licenses, which are from 7 to 20 years. Patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.
	Goodwill
	Goodwill represents the excess of cost over the fair value of tangible and identifiable intangible net assets acquired.  Annual impairment testing for goodwill is done using a qualitative assessment on goodwill impairment to determine whether it is necessary to perform the two-step goodwill impairment test.  Goodwill is also reviewed whenever events or changes in circumstances indicate a change in value may have occurred.  We have identified three reporting units where goodwill was recorded for purposes of testing goodwill impairment annually: (1) Atrion Medical Products, Inc., (2) Halkey-Roberts Corporation and (3) Quest Medical, Inc.  The total carrying amount of goodwill in each of the years ended December 31, 2013, 2012 and 2011 was $9,730,000. Our evaluation of goodwill during the year resulted in no impairment losses.
	Current Accrued Liabilities
	The items comprising current accrued liabilities are as follows (in thousands):
		December 31,
		2013		2012
	Accrued payroll and related expenses	$	3,711	$	2,276
	Accrued vacation		229		210
	Other accrued liabilities		483		414
	Total accrued liabilities	$	4,423	$	2,900
	Revenues
	We recognize revenue when our products are shipped to our customers, provided an arrangement exists, the fee is fixed and determinable and collectability is reasonably assured. All risks and rewards of ownership pass to the customer upon shipment. Net sales represent gross sales invoiced to customers, less certain related charges, including discounts, returns and other allowances. Revenues are recorded exclusive of sales and similar taxes. Returns, discounts and other allowances have been insignificant historically.
	Shipping and Handling Policy
	Shipping and handling fees charged to customers are reported as revenue and all shipping and handling costs incurred related to products sold are reported as cost of goods sold.
	Research and Development Costs
	Research and development costs relating to the development of new products and improvements of existing products are expensed as incurred.
	Stock-Based Compensation
	We have stock-based compensation plans covering certain of our officers, directors and key employees. As explained in detail in Note 8, we account for stock-based compensation utilizing the fair value recognition provisions of ASC 718, Compensation-Stock Compensation, (“ASC 718”).
	New Accounting Pronouncements
	From time to time, new accounting pronouncements applicable to us are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies, which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.
	Fair Value Measurements
	Accounting standards use a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists therefore requiring an entity to develop its own assumptions.
	As of December 31, 2013 and 2012, we held certain investments that were required to be measured for disclosure purposes at fair value on a recurring basis.  These investments are considered Level 2 assets. The fair value of our investments is estimated using recently executed transactions and market price quotations. At December 31, 2013 and 2012, the fair value of our investments approximated or exceeded the carrying value of the investments (see Note 2).
	The carrying values of our other financial instruments including cash and cash equivalents, money market accounts, accounts receivable, accounts payable, accrued liabilities, and accrued income and other taxes approximated fair value due to their liquid and short-term nature.
	Concentration of Credit Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable.
Our cash is held in high credit quality financial institutions. As of December 31, 2013, we had $28.6 million in cash and cash equivalents invested as follows: $2.6 million invested in money market mutual funds and $26.0 million held in depository accounts. From time to time, deposits held with financial institutions exceed the amount of Federal Deposit Insurance Corporation, or FDIC, insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. At December 31, 2013, our uninsured cash and cash equivalents totaled approximately $27.0 million.
For accounts receivable, we perform ongoing credit evaluations of our customers’ financial condition and generally do not require collateral.  We maintain reserves for possible credit losses.  As of December 31, 2013 and 2012, we had allowances for doubtful accounts of approximately $86,000 and $47,000, respectively.  The carrying amount of the receivables approximates their fair value. Our customer that generates our largest revenues accounted for 8.2%, 16.3% and 6.7% of accounts receivable as of December 31, 2013, 2012 and 2011, respectively.  No other customer exceeded 10% of our accounts receivable as of December 31, 2013, 2012 or 2011.

Investments

Investments	12 Months Ended
	Dec. 31, 2013
Investments	'
	(2) Investments
	As of December 31, 2013 and 2012, we held certain investments that were required to be measured for disclosure purposes at fair value on a recurring basis. These investments were considered Level 2 investments. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets.
	The amortized cost and fair value of our investments that are being accounted for as held-to-maturity securities, and the related gross unrealized gains and losses, were as follows as of the dates shown below (in thousands):
				Gross Unrealized
		Cost		Gains		Losses		Fair value
	As of December 31, 2013:
	Short-term Investments:
	Corporate bonds	$	18,351	$	234	$	—	$	18,585
	Long-term Investments:
	Corporate bonds	$	10,069	$	285	$	—	$	10,354
	As of December 31, 2012:
	Short-term Investments:
	Corporate bonds	$	8,182	$	78	$	—	$	8,260
	Long-term Investments:
	Corporate bonds	$	28,433	$	652	$	29	$	29,056
	At December 31, 2013, the length of time until maturity of these securities ranged from five to 16 months.

Patents_and_Licenses

Patents and Licenses	12 Months Ended
	Dec. 31, 2013
Patents and Licenses	'
	(3) Patents and Licenses
	Purchased patents and licenses paid for the use of other entities’ patents are amortized over the useful life of the patent or license.  The following tables provide information regarding patents and licenses (dollars in thousands):
	31-Dec-13						31-Dec-12
	Weighted Average		Gross		Accumulated		Weighted Average		Gross		Accumulated
	Original Life		Carrying		Amortization		Original Life		Carrying		Amortization
	(years)		Amount				(years)		Amount
		18.55	$	13,840	$	11,032		14.88	$	11,690	$	10,853
	Aggregate amortization expense for patents and licenses was $179,000 for 2013, $162,000 for 2012 and $272,000 for 2011.  Estimated future amortization expense for each of the years set forth below ending December 31, is as follows (in thousands):
	2014	$269
	2015	$269
	2016	$269
	2017	$173
	2018	$141

Line_of_Credit

Line of Credit	12 Months Ended
	Dec. 31, 2013
Line of Credit	'
	(4) Line of Credit
	We have a revolving credit facility with a money center bank which is secured by substantially all our inventories, equipment and accounts receivable. Effective October 1, 2011, our credit facility was amended to increase the maximum principal amount of our revolving line of credit from $25.0 million to $40.0 million. Interest under the credit facility is assessed at 30-day, 60-day or 90-day LIBOR, as selected by us, plus one percent (1.17 percent at December 31, 2013) and is payable monthly. We had no outstanding borrowings under the credit facility at December 31, 2013 or 2012.  The credit facility amendment also extended the date on which the lender is obligated to make advances under the revolving line of credit to October 1, 2016.  At any time during the term, we may convert any or all outstanding amounts under the credit facility to a term loan with a maturity of two years. Our ability to borrow funds under the credit facility from time to time is contingent on meeting certain covenants in the loan agreement, the most restrictive of which is the ratio of total debt to earnings before interest, income tax, depreciation and amortization.  At December 31, 2013, we were in compliance with all of those covenants.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
	(5) Income Taxes
	The items comprising income tax expense are as follows (in thousands):
		Year ended December 31,
		2013			2012			2011
	Current                  —   Federal	$	12,541		$	8,934		$	9,973
	—   State		1,065			1,050			880
			13,606			9,984			10,853
	Deferred               —    Federal		(1,063	)		1,363			2,372
	—    State		140			99			212
			(923	)		1,462			2,584
	Total income tax expense	$	12,683		$	11,446		$	13,437
	Temporary differences and carryforwards which have given rise to deferred income tax assets and liabilities as of December 31, 2013 and 2012 are as follows (in thousands):
		2013			2012
	Deferred tax assets:
	Benefit plans	$	1,590		$	1,099
	Inventories		525			536
	Other		37			38
	Total deferred tax assets	$	2,152		$	1,673
	Deferred tax liabilities:
	Property, plant and equipment	$	9,716		$	10,299
	Patents and goodwill		2,956			2,972
	Other		166			11
	Total deferred tax liabilities	$	12,838		$	13,282
	Net deferred tax liability	$	10,686		$	11,609
	Balance Sheet classification:
	Non-current deferred income tax liability	$	12,062		$	12,232
	Current deferred income tax asset		1,376			623
	Net deferred tax liability	$	10,686		$	11,609
	Total income tax expense differs from the amount that would be provided by applying the statutory federal income tax rate to pretax earnings as illustrated below (in thousands):
		Year ended December 31,
		2013			2012			2011
	Income tax expense at the statutory	$	13,743		$	12,276		$	13,816
	federal income tax rate
	Increase (decrease) resulting from:
	State income taxes		770			747			710
	Section 199 manufacturing deduction		(1,307	)		(949	)		(996	)
	Other, net		(523	)		(628	)		(93	)
	Total income tax expense	$	12,683		$	11,446		$	13,437
	A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits as required by ASC 740 is as follows (in thousands):
	Gross unrecognized tax benefits at January 1, 2011	$	1,420
	Decreases in tax positions for prior years		(77	)
	Increases in tax positions for current year		134
	Lapse in statutes of limitation		(216	)
	Gross unrecognized tax benefits at December 31, 2011	$	1,261
	Increase in tax positions for prior years		19
	Increase in tax positions for current year		0
	Decrease due to settlement with taxing authorities		(641	)
	Lapse in statutes of limitation		(98	)
	Gross unrecognized tax benefits at December 31, 2012	$	541
	Increase in tax positions for prior years		11
	Increase in tax positions for current year		0
	Lapse in statutes of limitation		(206	)
	Gross unrecognized tax benefits at December 31, 2013	$	346
	As of December 31, 2013 all of the unrecognized tax benefits, which were comprised of uncertain tax positions, would impact the effective tax rate if recognized. Unrecognized tax benefits that are affected by statutes of limitation that expire within the next 12 months are immaterial.
	We are subject to United States federal income tax as well as to income tax of multiple state jurisdictions.  We have concluded all United States federal income tax matters for years through 2009.  In January 2009, the Internal Revenue Service (“IRS”) began examining certain of our United States federal income tax returns for 2006, 2007 and 2008. This audit was favorably concluded in the third quarter of 2012 when the IRS appeals group allowed 100% of the tax credits claimed for our research and development during those years. Our unrecognized tax benefits were reduced at that time on the basis of this favorable settlement in the amount of approximately $641,000. All material state and local income tax matters have been concluded for years through 2009.
	We recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The liability for unrecognized tax benefits included accrued interest of $21,000, $26,000 and $77,000 at December 31, 2013, 2012 and 2011, respectively. Tax expense for the year ended December 31, 2013, 2012 and 2011 included a net interest benefit of $5,400, $51,000 and $7,000, respectively.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity	'
	(6) Stockholders’ Equity
	Our Board of Directors has at various times authorized repurchases of our stock in open-market or negotiated transactions at such times and at such prices as management may from time to time determine. On August 16, 2011, our Board of Directors adopted a new stock repurchase program pursuant to which we can repurchase up to 200,000 shares of our common stock from time to time in open market or privately-negotiated transactions. This stock repurchase program has no expiration date but may be terminated by the Board of Directors at any time. As of December 31, 2012, 165,438 shares remained available for repurchase under this program. In 2013, we repurchased 36,666 shares under this program, including 6,704 shares from executive officers in transactions during an open window period for trading, and that were pre-cleared, under our Insider Trading Policy. In 2012 and 2011, we repurchased 26,562 and 8,000 shares, respectively, and as of December 31, 2013 there remained 128,772 shares available for repurchase under the program.
	We have increased our quarterly cash dividend payments in September of each of the past three years. The quarterly dividend was increased to $.49 per share in September 2011, to $.56 per share in September 2012 and to $.64 in September 2013.  On December 10, 2012 we also paid a special cash dividend to stockholders of $10.00 per share. Holders of stock units earned non-cash dividends of $29,000 in 2013, $157,000 in 2012 and $30,000 in 2011.
	We have a Rights Plan, which is intended to protect the interests of stockholders in the event of a hostile attempt to take over the Company.  The rights, which are not presently exercisable and do not have any voting powers, represent the right of our stockholders to purchase at a substantial discount, upon the occurrence of certain events, shares of our common stock or of an acquiring company involved in a business combination with us.  This plan, which was adopted in August 2006, expires in August 2016.

Income_Per_Share

Income Per Share	12 Months Ended
	Dec. 31, 2013
Income Per Share	'
	(7) Income Per Share
	The following is the computation of basic and diluted income per share:
		Year ended December 31,
		2013		2012		2011
		(In thousands, except per share amounts)
	Net Income	$	26,582	$	23,629	$	26,038
	Weighted average basic shares outstanding		2,010		2,016		2,019
	Add:  Effect of dilutive securities		7		11		12
	Weighted average diluted shares outstanding		2,017		2,027		2,031
	Net Income per share
	Basic	$	13.22	$	11.72	$	12.9
	Diluted	$	13.18	$	11.66	$	12.82
	As required by ASC 260, Earnings per Share, unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are considered participating securities and, therefore, are included in the computation of basic income per share pursuant to the two-class method.
	Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method.  Dilutive securities representing 4,344 shares of common stock for the year ended December 31, 2013 were excluded from the computation of weighted average diluted shares outstanding because their effect would have been anti-dilutive.

Stock_Plans

Stock Plans	12 Months Ended
	Dec. 31, 2013
Stock Plans	'
	(8) Stock Plans
	At December 31, 2013, we had three stock-based compensation plans which are described more fully below. We account for our plans under ASC 718, and the disclosures that follow are based on applying ASC 718. ASC 718 requires that cash flows from the use of stock-based compensation resulting from tax benefits in excess of recognized compensation cost (excess tax benefits) be classified as financing cash flows. We recorded $15,000, $1,412,000 and $79,000 of such excess tax benefits as financing cash flows in 2013, 2012 and 2011, respectively.
	Our Amended and Restated 2006 Equity Incentive Plan (the “2006 Plan”) provides for the grant to key employees, non-employee directors and consultants of incentive and nonqualified stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance shares and other stock-based awards. Under the 2006 Plan, 200,000 shares, in the aggregate, of common stock have been reserved for awards. The purchase price of shares issued on the exercise of options must be at least equal to the fair market value of such shares on the date of grant.  The options granted become exercisable and expire as determined by the Compensation Committee.  As of December 31, 2013, there remained 58,242 shares for future stock-based awards under the 2006 Plan.
	In May 2007, we adopted our Deferred Compensation Plan for Non-Employee Directors (as amended, the “Deferred Compensation Plan”), and 2,500 shares of our common stock were initially reserved for issuance thereunder. This plan allows our non-employee directors to elect to receive stock units in lieu of all or part of the cash fees they are receiving for their services as directors.  On the first business day of each calendar year, each participating non-employee director is credited with a number of stock units determined on the basis of the foregone cash fees and the closing price of our common stock on the next preceding date on which shares of our stock were traded.  The stock units are converted to shares of our common stock on a one-for-one basis at a future date as elected in advance by the director, but no later than the January following the year in which the director ceases to serve on the Board of Directors, and the shares are delivered to the director.   As of December 31, 2013, there remained 1,626 shares of common stock reserved for issuance upon the conversion of stock units which may be credited in the future to non-employee directors.
	In May 2007, we also adopted our Non-Employee Director Stock Purchase Plan, (as amended, the “Director Stock Purchase Plan”), and 2,500 shares of our common stock were initially reserved for issuance thereunder. Under this plan, our non-employee directors may elect to receive on the first business day of the calendar year fully-vested stock and restricted stock in lieu of some or all of their fees payable to them during such year. The foregone fees are converted into shares of fully-vested stock and restricted stock on the first business day of such calendar year based on the closing price of our common stock on the next preceding date on which shares of our stock were traded. The restricted stock vests in equal amounts on the first day of the next three succeeding calendar quarters provided the non-employee director is then serving on our Board of Directors. As of December 31, 2013, there remained 1,126 shares reserved for issuance under such plan.
	A summary of stock option transactions for the year ended December 31, 2013 is presented below:
	Options	Shares			Weighted Average Exercise Price			Weighted
								Average
								Remaining
								Contractual
								Term
	Outstanding at December 31, 2012		50,000		$	204.76
	Granted		--			--
	Exercised		--			--
	Outstanding at December 31, 2013		50,000		$	204.76		4.9 years
	Exercisable at December 31, 2013		15,000		$	196.99		4.7 years
	All nonvested options outstanding at December 31, 2013 are expected to vest.  We estimate the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. None of our grants includes performance-based or market-based vesting conditions.  The expected life represents the period that our stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. The fair value of stock-based payments, funded with options, is valued using the Black-Scholes valuation method with a volatility factor based on our historical stock trading history. We base the risk-free interest rate using the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury securities with an equivalent term. We base the dividend yield used in the Black-Scholes valuation method on our dividend history.
	There were no options granted in 2013.  The fair value for the options granted in 2012 and 2011 was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:
		2013			2012				2011
	Risk-free interest rate		--			0.5	%			1.7	%
	Dividend yield		--			1	%			1	%
	Volatility factor		--			25	%			25	%
	Expected life		--		5 years				5 years
	The weighted average grant date fair value of the options granted in 2012 and 2011 was $40.38 and $40.64, respectively. The total intrinsic value of options exercised during 2012 was $3.1 million. There were no options exercised in 2013 and 2011.  The total intrinsic values of options outstanding and options currently exercisable at December 31, 2013, were $4.6 million and $1.5 million, respectively.
	During 2013, we made no awards of restricted stock under the 2006 Plan.  Under the terms of our restricted stock awards, the restrictions usually lapse over a five-year period. During the vesting period, holders of restricted stock have voting rights and earn dividends, but the shares may not be sold, assigned, transferred, pledged or otherwise encumbered. Nonvested shares are generally forfeited on termination of employment unless otherwise provided in the participant’s employment agreement or the termination is in connection with a change in control.  A summary of changes in nonvested restricted stock for the year ended December 31, 2013 is presented below:
	Nonvested Shares		Shares			Weighted Average
						Award Date Fair
						Value Per Share
	Restricted stock at December 31, 2012		13,500		$	207.35
	Granted in 2013		--			--
	Vested in 2013		(3,000	)	$	211.06
	Restricted stock at December 31, 2013		10,500		$	208.09
	All shares of nonvested restricted stock outstanding at December 31, 2013 are expected to vest. The total fair value of restricted stock vested during 2013, 2012 and 2011 was $633,000, $559,000 and $481,000, respectively.
	During 2013, restricted stock units were awarded to certain employees under the 2006 Plan.  All of our restricted stock units are convertible to shares of stock on a one-for-one basis when the restrictions lapse, which is generally after a five-year period. Nonvested stock units are generally forfeited on termination of employment unless the termination is in connection with a change in control. During the vesting period, holders of all restricted stock units earn dividends in the form of additional units.   During 2013, one non-employee director elected to receive stock units in lieu of a portion of his cash fees for his services as a member of the Board of Directors.
	A summary of changes in stock units for the year ended December 31, 2013, is presented below:
	Nonvested Stock Units				Weighted							Weighted
					Average							Average
		Restricted			Award Date				Director’s			Award Date
		Stock Units			Fair Value				Stock Units			Fair Value
					Per Unit							Per Unit
	Nonvested at December 31, 2012		11,996		$	194.95				--
	Granted		908		$	214.76				41		$	199.78
	Vested		--			--				(41	)	$	199.78
	Nonvested at December 31, 2013		12,904		$	196.35				--
	All nonvested restricted stock units at December 31, 2013 are expected to vest.  The total intrinsic value of all outstanding stock units which were not convertible at December 31, 2013, including 389 stock units held for the accounts of non-employee directors, was $3,938,000.  There were no vested restricted stock units during 2013.  The total fair value of directors’ stock units vested during 2013, 2012 and 2011 was $8,000, $22,000 and $8,000, respectively.
	Stock awards that vest immediately were awarded under the 2006 Plan to non-employee directors in 2013, 2012 and 2011 totaling $120,000 in value in each year.  Compensation related to stock awards, restricted stock and stock units is based on the fair market value of the stock on the date of the grant. These fair values are then amortized on a straight-line basis over the requisite service periods of the entire awards, which is generally the vesting period. Compensation related to stock options is based on the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. For the years ended December 31, 2013, 2012 and 2011, we recorded stock-based compensation expense as a “General and Administrative expense” in the amount of $1,586,000, $1,482,000 and $1,047,000, respectively, for all of the above mentioned stock-based compensation arrangements. The total tax benefit recognized in the income statement from stock-based compensation arrangements for the years ended December 31, 2013, 2012 and 2011, was $555,000, $516,000 and $359,000, respectively.
	Unrecognized compensation cost information for our various stock-based compensation types is shown below as of December 31, 2013:
		Unrecognized Compensation Cost			Weighted Average
					Remaining Years in Amortization Period
	Stock options	$	1,172,000			3
	Restricted stock		1,812,000			3
	Restricted stock units		1,355,000			3.3
	Total	$	4,339,000
	We have a policy of utilizing treasury shares to satisfy stock option exercises, stock unit conversions and restricted stock awards.

Revenues_From_Major_Customers

Revenues From Major Customers	12 Months Ended
	Dec. 31, 2013
Revenues From Major Customers	'
	(9) Revenues From Major Customers
	We had one major customer which represented approximately $13.5 million (10.2 percent) and $15.1 million (12.9 percent) of our net revenues during 2013 and 2011, respectively.

Industry_Segment_and_Geographi

Industry Segment and Geographic Information	12 Months Ended
	Dec. 31, 2013
Industry Segment and Geographic Information	'
	(10) Industry Segment and Geographic Information
	We operate in one reportable industry segment: developing and manufacturing products primarily for medical applications and have no foreign operating subsidiaries.  We have other product lines which include pressure relief valves and inflation systems, which are sold primarily to the aviation and marine industries. Due to the similarities in product technologies and manufacturing processes, these products are managed as part of our medical products segment. Our revenues from sales to customers outside the United States totaled approximately 42 percent of our net revenues in 2013, 2012 and 2011.  We have no assets located outside the United States.
	A summary of revenues by geographic territory, based on shipping destination, for 2013, 2012 and 2011 is as follows (in thousands):
		Year ended December 31,
		2013		2012		2011
	United States	$	75,997	$	69,388	$	68,156
	Canada		15,114		13,352		17,524
	Other countries less than 10% of revenues		40,882		36,322		32,024
	Total	$	131,993	$	119,062	$	117,704
	A summary of revenues by product line for 2013, 2012 and 2011 is as follows (in thousands):
		2013		2012		2011
	Fluid Delivery	$	51,289	$	49,060	$	45,274
	Cardiovascular		40,182		36,021		34,072
	Ophthalmology		20,736		15,717		19,581
	Other		19,786		18,264		18,777
	Total	$	131,993	$	119,062	$	117,704

Employee_Retirement_and_Benefi

Employee Retirement and Benefit Plans	12 Months Ended
	Dec. 31, 2013
Employee Retirement and Benefit Plans	'
	(11) Employee Retirement and Benefit Plans
	We sponsor a defined contribution 401(k) plan for all employees. Each participant may contribute certain amounts of eligible compensation. We make a matching contribution to the plan. Our contributions under this plan were $561,000, $533,000 and $487,000 in 2013, 2012 and 2011, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
	(12) Commitments and Contingencies
	From time to time and in the ordinary course of business, we may be subject to various claims, charges and litigation. In some cases, the claimants may seek damages, as well as other relief, which, if granted, could require significant expenditures. We accrue the estimated costs of settlement or damages when a loss is deemed probable and such costs are estimable, and accrue for legal costs associated with a loss contingency when a loss is probable and such amounts are estimable. Otherwise, these costs are expensed as incurred. If the estimate of a probable loss or defense costs is a range and no amount within the range is more likely, we accrue the minimum amount of the range. As of December 31, 2013, the Company had no ongoing litigation or arbitration for such matters.
	We had a dispute which was favorably settled in the third quarter of 2007. This settlement was amended in December 2008.  The amended settlement agreement provides that we may receive annual payments from 2009 through 2024. We have not recorded $5.5 million in potential future payments under this settlement as of December 31, 2013 due to the uncertainty of payment.
	We have arrangements with three of our executive officers pursuant to which the termination of their employment under certain circumstances would result in lump sum payments to them.  Termination under such circumstances at December 31, 2013 could have resulted in payments aggregating $4.3 million.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited)	'
	(13) Quarterly Financial Data (Unaudited):
	Quarter	Operating		Operating		Net Income		Income		Income
	Ended	Revenue		Income				Per Basic		Per Diluted
								Share		Share
	(In thousands, except per share amounts)
	3/31/13	$	33,493	$	9,400	$	6,635	$	3.28	$	3.28
	6/30/13		32,605		9,495		6,506		3.23		3.22
	9/30/13		34,044		10,713		7,673		3.82		3.81
	12/31/13		31,851		8,336		5,768		2.88		2.87
	3/31/12	$	29,239	$	7,943	$	5,377	$	2.67	$	2.65
	6/30/12		30,689		8,967		6,099		3.03		3.02
	9/30/12		30,637		9,677		7,259		3.6		3.59
	12/31/12		28,497		7,039		4,894		2.42		2.42
	The quarterly information presented above reflects, in the opinion of management, all adjustments necessary for a fair presentation of the results for the interim periods presented.

Schedule_II_Consolidated_Valua

Schedule II - Consolidated Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Schedule II - Consolidated Valuation and Qualifying Accounts	'
	Schedule II – Consolidated Valuation and Qualifying Accounts
		Allowance for Doubtful Receivables
		December 31,
		2013			2012			2011
		(in thousands)
	Beginning balance	$	47		$	42		$	36
	Additions charged to expense		69			36			40
	Deductions from reserve		(29	)		(31	)		(23	)
	Recovery		(1	)		-			(11	)
	Ending balance	$	86		$	47		$	42

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Atrion Corporation and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Estimates	'
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash equivalents include cash on hand and in the bank as well as money market accounts and debt securities with original maturities of 90 days or less.
Trade Receivables	'
	Trade Receivables
	Trade accounts receivable are recorded at the original sales price to the customer.  We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments.  On an ongoing basis, the collectability of accounts receivable is assessed based upon historical collection trends, current economic factors and the assessment of the collectability of specific accounts.  We evaluate the collectability of specific accounts and determine when to grant credit to our customers using a combination of factors, including the age of the outstanding balances, evaluation of customers’ current and past financial condition, recent payment history, current economic environment, and discussions with appropriate Company personnel and with the customers directly.  Accounts are written off when we determine the receivable will not be collected.
Investments	'
	Investments
	Our investments consist of taxable corporate bonds. Our investment policy is to seek to preserve principal and maintain adequate liquidity while at the same time maximizing yields without significantly increasing risk. We are required to classify our investments as trading, available-for-sale or held-to-maturity. Our investments are accounted for as held-to-maturity since we have the positive intent and ability to hold these investments to maturity. These investments are reported at cost, adjusted for premiums and discounts that are recognized in interest income, using a method that approximates the effective interest method, over the period to maturity and unrealized gains and losses are excluded from earnings. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost (including materials, direct labor and applicable overhead) or market. Cost is determined by using the first-in, first-out method. The following table details the major components of inventory (in thousands):
		December 31,
		2013		2012
	Raw materials	$	10,744	$	10,017
	Work in process		6,246		5,268
	Finished goods		9,276		8,494
	Total inventories	$	26,266	$	23,779
Accounts Payable	'
	Accounts Payable
	We reflect disbursements as trade accounts payable until such time as payments are presented to our bank for payment. At December 31, 2013 and 2012, disbursements totaling approximately $443,000 and $495,000, respectively, had not been presented for payment to our bank.
Income Taxes	'
	Income Taxes
	We account for income taxes utilizing Accounting Standards Codification (ASC) 740, Income Taxes (“ASC 740”).  ASC 740 requires the asset and liability method for the recording of deferred income taxes, whereby deferred tax assets and liabilities are recognized based on the tax effects of temporary differences between the financial statement and the tax bases of assets and liabilities, as measured at current enacted tax rates. When appropriate, we evaluate the need for a valuation allowance to reduce deferred tax assets.
	ASC 740 also requires the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attributes of income tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more-likely-than-not of being sustained.
	Our uncertain tax positions are recorded as “Other non-current liabilities.” We classify interest expense on underpayments of income taxes and accrued penalties related to unrecognized tax benefits in the income tax provision.
Property Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Additions and improvements are capitalized, including all material, labor and engineering costs to design, install or improve the asset. Expenditures for repairs and maintenance are charged to expense as incurred. The following table represents a summary of property, plant and equipment at original cost (in thousands):
		December 31,				Useful
		2013		2012		Lives
	Land	$	5,260	$	5,260	—
	Buildings		31,314		30,664	30-40 yrs
	Machinery and equipment		93,930		88,256	3-15 yrs
	Total property, plant and equipment	$	130,504	$	124,180
	Depreciation expense of $8,413,000, $7,448,000 and $6,272,000 was recorded for the years ended December 31, 2013, 2012 and 2011, respectively. Depreciation expense is recorded in either cost of goods sold or operating expenses based on the associated assets’ usage.
Patents and Licenses	'
	Patents and Licenses
	Costs for patents and licenses acquired are determined at acquisition date. Patents and licenses are amortized over the useful lives of the individual patents and licenses, which are from 7 to 20 years. Patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.
Goodwill	'
	Goodwill
	Goodwill represents the excess of cost over the fair value of tangible and identifiable intangible net assets acquired.  Annual impairment testing for goodwill is done using a qualitative assessment on goodwill impairment to determine whether it is necessary to perform the two-step goodwill impairment test.  Goodwill is also reviewed whenever events or changes in circumstances indicate a change in value may have occurred.  We have identified three reporting units where goodwill was recorded for purposes of testing goodwill impairment annually: (1) Atrion Medical Products, Inc., (2) Halkey-Roberts Corporation and (3) Quest Medical, Inc.  The total carrying amount of goodwill in each of the years ended December 31, 2013, 2012 and 2011 was $9,730,000. Our evaluation of goodwill during the year resulted in no impairment losses.
Current Accrued Liabilities	'
	Current Accrued Liabilities
	The items comprising current accrued liabilities are as follows (in thousands):
		December 31,
		2013		2012
	Accrued payroll and related expenses	$	3,711	$	2,276
	Accrued vacation		229		210
	Other accrued liabilities		483		414
	Total accrued liabilities	$	4,423	$	2,900
Revenues	'
	Revenues
	We recognize revenue when our products are shipped to our customers, provided an arrangement exists, the fee is fixed and determinable and collectability is reasonably assured. All risks and rewards of ownership pass to the customer upon shipment. Net sales represent gross sales invoiced to customers, less certain related charges, including discounts, returns and other allowances. Revenues are recorded exclusive of sales and similar taxes. Returns, discounts and other allowances have been insignificant historically.
Shipping and Handling Policy	'
	Shipping and Handling Policy
	Shipping and handling fees charged to customers are reported as revenue and all shipping and handling costs incurred related to products sold are reported as cost of goods sold.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs relating to the development of new products and improvements of existing products are expensed as incurred.
Stock-Based Compensation	'
	Stock-Based Compensation
	We have stock-based compensation plans covering certain of our officers, directors and key employees. As explained in detail in Note 8, we account for stock-based compensation utilizing the fair value recognition provisions of ASC 718, Compensation-Stock Compensation, (“ASC 718”).
New Accounting Pronouncements	'
	New Accounting Pronouncements
	From time to time, new accounting pronouncements applicable to us are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies, which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.
Fair Value Measurements	'
	Fair Value Measurements
	Accounting standards use a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists therefore requiring an entity to develop its own assumptions.
	As of December 31, 2013 and 2012, we held certain investments that were required to be measured for disclosure purposes at fair value on a recurring basis.  These investments are considered Level 2 assets. The fair value of our investments is estimated using recently executed transactions and market price quotations. At December 31, 2013 and 2012, the fair value of our investments approximated or exceeded the carrying value of the investments (see Note 2).
	The carrying values of our other financial instruments including cash and cash equivalents, money market accounts, accounts receivable, accounts payable, accrued liabilities, and accrued income and other taxes approximated fair value due to their liquid and short-term nature.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable.
	Our cash is held in high credit quality financial institutions. As of December 31, 2013, we had $28.6 million in cash and cash equivalents invested as follows: $2.6 million invested in money market mutual funds and $26.0 million held in depository accounts. From time to time, deposits held with financial institutions exceed the amount of Federal Deposit Insurance Corporation, or FDIC, insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. At December 31, 2013, our uninsured cash and cash equivalents totaled approximately $27.0 million.
	For accounts receivable, we perform ongoing credit evaluations of our customers’ financial condition and generally do not require collateral.  We maintain reserves for possible credit losses.  As of December 31, 2013 and 2012, we had allowances for doubtful accounts of approximately $86,000 and $47,000, respectively.  The carrying amount of the receivables approximates their fair value. Our customer that generates our largest revenues accounted for 8.2%, 16.3% and 6.7% of accounts receivable as of December 31, 2013, 2012 and 2011, respectively.  No other customer exceeded 10% of our accounts receivable as of December 31, 2013, 2012 or 2011.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Major Components of Inventories	'
	The following table details the major components of inventory (in thousands):
		December 31,
		2013		2012
	Raw materials	$	10,744	$	10,017
	Work in process		6,246		5,268
	Finished goods		9,276		8,494
	Total inventories	$	26,266	$	23,779
Summary of Property Plant and Equipment at Original Cost	'
	The following table represents a summary of property, plant and equipment at original cost (in thousands):
		December 31,				Useful
		2013		2012		Lives
	Land	$	5,260	$	5,260	—
	Buildings		31,314		30,664	30-40 yrs
	Machinery and equipment		93,930		88,256	3-15 yrs
	Total property, plant and equipment	$	130,504	$	124,180
Current Accrued Liabilities	'
	The items comprising current accrued liabilities are as follows (in thousands):
		December 31,
		2013		2012
	Accrued payroll and related expenses	$	3,711	$	2,276
	Accrued vacation		229		210
	Other accrued liabilities		483		414
	Total accrued liabilities	$	4,423	$	2,900

Investments_Tables

Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Investments, Held-to-Maturity Securities	'
	The amortized cost and fair value of our investments that are being accounted for as held-to-maturity securities, and the related gross unrealized gains and losses, were as follows as of the dates shown below (in thousands):
				Gross Unrealized
		Cost		Gains		Losses		Fair value
	As of December 31, 2013:
	Short-term Investments:
	Corporate bonds	$	18,351	$	234	$	—	$	18,585
	Long-term Investments:
	Corporate bonds	$	10,069	$	285	$	—	$	10,354
	As of December 31, 2012:
	Short-term Investments:
	Corporate bonds	$	8,182	$	78	$	—	$	8,260
	Long-term Investments:
	Corporate bonds	$	28,433	$	652	$	29	$	29,056

Patents_and_Licenses_Tables

Patents and Licenses (Tables)	12 Months Ended
	Dec. 31, 2013
Information Regarding Patents and Licenses	'
	The following tables provide information regarding patents and licenses (dollars in thousands):
	31-Dec-13						31-Dec-12
	Weighted Average		Gross		Accumulated		Weighted Average		Gross		Accumulated
	Original Life		Carrying		Amortization		Original Life		Carrying		Amortization
	(years)		Amount				(years)		Amount
		18.55	$	13,840	$	11,032		14.88	$	11,690	$	10,853
Estimated Future Amortization Expense	'
	Estimated future amortization expense for each of the years set forth below ending December 31, is as follows (in thousands):
	2014	$269
	2015	$269
	2016	$269
	2017	$173
	2018	$141

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Expense	'
	The items comprising income tax expense are as follows (in thousands):
		Year ended December 31,
		2013			2012			2011
	Current                  —   Federal	$	12,541		$	8,934		$	9,973
	—   State		1,065			1,050			880
			13,606			9,984			10,853
	Deferred               —    Federal		(1,063	)		1,363			2,372
	—    State		140			99			212
			(923	)		1,462			2,584
	Total income tax expense	$	12,683		$	11,446		$	13,437
Deferred Income Tax Assets and Liabilities with Temporary Differences and Carryforwards	'
	Temporary differences and carryforwards which have given rise to deferred income tax assets and liabilities as of December 31, 2013 and 2012 are as follows (in thousands):
		2013			2012
	Deferred tax assets:
	Benefit plans	$	1,590		$	1,099
	Inventories		525			536
	Other		37			38
	Total deferred tax assets	$	2,152		$	1,673
	Deferred tax liabilities:
	Property, plant and equipment	$	9,716		$	10,299
	Patents and goodwill		2,956			2,972
	Other		166			11
	Total deferred tax liabilities	$	12,838		$	13,282
	Net deferred tax liability	$	10,686		$	11,609
	Balance Sheet classification:
	Non-current deferred income tax liability	$	12,062		$	12,232
	Current deferred income tax asset		1,376			623
	Net deferred tax liability	$	10,686		$	11,609
Illustration of Total Income Tax Expense Difference with Amount Provided by Applying Statutory Federal Income Tax Rate to Pretax Earnings	'
	Total income tax expense differs from the amount that would be provided by applying the statutory federal income tax rate to pretax earnings as illustrated below (in thousands):
		Year ended December 31,
		2013			2012			2011
	Income tax expense at the statutory	$	13,743		$	12,276		$	13,816
	federal income tax rate
	Increase (decrease) resulting from:
	State income taxes		770			747			710
	Section 199 manufacturing deduction		(1,307	)		(949	)		(996	)
	Other, net		(523	)		(628	)		(93	)
	Total income tax expense	$	12,683		$	11,446		$	13,437
Reconciliation of Beginning and Ending Balances of Total Amounts of Gross Unrecognized Tax Benefits	'
	A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits as required by ASC 740 is as follows (in thousands):
	Gross unrecognized tax benefits at January 1, 2011	$	1,420
	Decreases in tax positions for prior years		(77	)
	Increases in tax positions for current year		134
	Lapse in statutes of limitation		(216	)
	Gross unrecognized tax benefits at December 31, 2011	$	1,261
	Increase in tax positions for prior years		19
	Increase in tax positions for current year		0
	Decrease due to settlement with taxing authorities		(641	)
	Lapse in statutes of limitation		(98	)
	Gross unrecognized tax benefits at December 31, 2012	$	541
	Increase in tax positions for prior years		11
	Increase in tax positions for current year		0
	Lapse in statutes of limitation		(206	)
	Gross unrecognized tax benefits at December 31, 2013	$	346

Income_Per_Share_Tables

Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Computation of Basic and Diluted Income Per Share	'
	The following is the computation of basic and diluted income per share:
		Year ended December 31,
		2013		2012		2011
		(In thousands, except per share amounts)
	Net Income	$	26,582	$	23,629	$	26,038
	Weighted average basic shares outstanding		2,010		2,016		2,019
	Add:  Effect of dilutive securities		7		11		12
	Weighted average diluted shares outstanding		2,017		2,027		2,031
	Net Income per share
	Basic	$	13.22	$	11.72	$	12.9
	Diluted	$	13.18	$	11.66	$	12.82

Stock_Plans_Tables

Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Option Transaction	'
	A summary of stock option transactions for the year ended December 31, 2013 is presented below:
	Options	Shares			Weighted Average Exercise Price			Weighted
								Average
								Remaining
								Contractual
								Term
	Outstanding at December 31, 2012		50,000		$	204.76
	Granted		--			--
	Exercised		--			--
	Outstanding at December 31, 2013		50,000		$	204.76		4.9 years
	Exercisable at December 31, 2013		15,000		$	196.99		4.7 years
Black-Scholes Option Pricing Model Weighted Average Assumptions	'
	The fair value for the options granted in 2012 and 2011 was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:
		2013			2012				2011
	Risk-free interest rate		--			0.5	%			1.7	%
	Dividend yield		--			1	%			1	%
	Volatility factor		--			25	%			25	%
	Expected life		--		5 years				5 years
Restricted Stock Activity	'
	A summary of changes in nonvested restricted stock for the year ended December 31, 2013 is presented below:
	Nonvested Shares		Shares			Weighted Average
						Award Date Fair
						Value Per Share
	Restricted stock at December 31, 2012		13,500		$	207.35
	Granted in 2013		--			--
	Vested in 2013		(3,000	)	$	211.06
	Restricted stock at December 31, 2013		10,500		$	208.09
Changes in Stock Units	'
	A summary of changes in stock units for the year ended December 31, 2013, is presented below:
	Nonvested Stock Units				Weighted							Weighted
					Average							Average
		Restricted			Award Date				Director’s			Award Date
		Stock Units			Fair Value				Stock Units			Fair Value
					Per Unit							Per Unit
	Nonvested at December 31, 2012		11,996		$	194.95				--
	Granted		908		$	214.76				41		$	199.78
	Vested		--			--				(41	)	$	199.78
	Nonvested at December 31, 2013		12,904		$	196.35				--
Unrecognized Compensation Cost	'
	Unrecognized compensation cost information for our various stock-based compensation types is shown below as of December 31, 2013:
		Unrecognized Compensation Cost			Weighted Average
					Remaining Years in Amortization Period
	Stock options	$	1,172,000			3
	Restricted stock		1,812,000			3
	Restricted stock units		1,355,000			3.3
	Total	$	4,339,000

Industry_Segment_and_Geographi1

Industry Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2013
Revenues by Geographic Territory	'
	A summary of revenues by geographic territory, based on shipping destination, for 2013, 2012 and 2011 is as follows (in thousands):
		Year ended December 31,
		2013		2012		2011
	United States	$	75,997	$	69,388	$	68,156
	Canada		15,114		13,352		17,524
	Other countries less than 10% of revenues		40,882		36,322		32,024
	Total	$	131,993	$	119,062	$	117,704
Revenue by Product Line	'
	A summary of revenues by product line for 2013, 2012 and 2011 is as follows (in thousands):
		2013		2012		2011
	Fluid Delivery	$	51,289	$	49,060	$	45,274
	Cardiovascular		40,182		36,021		34,072
	Ophthalmology		20,736		15,717		19,581
	Other		19,786		18,264		18,777
	Total	$	131,993	$	119,062	$	117,704

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data	'
	Quarter	Operating		Operating		Net Income		Income		Income
	Ended	Revenue		Income				Per Basic		Per Diluted
								Share		Share
	(In thousands, except per share amounts)
	3/31/13	$	33,493	$	9,400	$	6,635	$	3.28	$	3.28
	6/30/13		32,605		9,495		6,506		3.23		3.22
	9/30/13		34,044		10,713		7,673		3.82		3.81
	12/31/13		31,851		8,336		5,768		2.88		2.87
	3/31/12	$	29,239	$	7,943	$	5,377	$	2.67	$	2.65
	6/30/12		30,689		8,967		6,099		3.03		3.02
	9/30/12		30,637		9,677		7,259		3.6		3.59
	12/31/12		28,497		7,039		4,894		2.42		2.42

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Significant Accounting Policies [Line Items]	'	'	'	'
Trade accounts payable	$443,000	$495,000	'	'
Depreciation expense	8,413,000	7,448,000	6,272,000	'
Goodwill, carrying amount	9,730,000	9,730,000	9,730,000	'
Goodwill, impairment loss	0	'	'	'
Cash and cash equivalents	28,559,000	7,999,000	24,590,000	10,670,000
Money market mutual fund	2,600,000	'	'	'
Cash and cash equivalents, held in depository accounts	26,000,000	'	'	'
Uninsured Cash and Cash Equivalents	27,000,000	'	'	'
Allowances for doubtful accounts	$86,000	$47,000	'	'
Maximum	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Cash equivalents, original maturities	'90 days	'	'	'
Credit Concentration Risk | Accounts Receivable	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Largest customer, percentage of accounts receivable	8.20%	16.30%	6.70%	'
Patents and licenses | Maximum	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Patents and licenses, useful lives	'20 years	'	'	'
Patents and licenses | Minimum	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Patents and licenses, useful lives	'7 years	'	'	'

Major_Components_of_Inventorie

Major Components of Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventories	'	'
Raw materials	$10,744	$10,017
Work in process	6,246	5,268
Finished goods	9,276	8,494
Total inventories	$26,266	$23,779

Summary_of_Property_Plant_and_

Summary of Property Plant and Equipment at Original Cost (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			Land	Buildings	Buildings	Machinery and equipment	Machinery and equipment
				Minimum	Maximum	Minimum	Maximum
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'
Land	$5,260	$5,260	'	'	'	'	'
Buildings	31,314	30,664	'	'	'	'	'
Machinery and equipment	93,930	88,256	'	'	'	'	'
Total property, plant and equipment	$130,504	$124,180	'	'	'	'	'
Property, plant and equipment, useful lives	'	'	'0 years	'30 years	'40 years	'3 years	'15 years

Current_Accrued_Liabilities_De

Current Accrued Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Accrued Liabilities [Line Items]	'	'
Accrued payroll and related expenses	$3,711	$2,276
Accrued vacation	229	210
Other accrued liabilities	483	414
Total accrued liabilities	$4,423	$2,900

Investments_HeldtoMaturity_Sec

Investments Held-to-Maturity Securities (Detail) (Corporate bonds, USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Short-term Investments	'	'
Schedule of Held-to-maturity Securities	'	'
Cost	$18,351	$8,182
Gross Unrealized Gains	234	78
Fair Value	18,585	8,260
Long Term Investments	'	'
Schedule of Held-to-maturity Securities	'	'
Cost	10,069	28,433
Gross Unrealized Gains	285	652
Gross Unrealized Losses	'	29
Fair Value	$10,354	$29,056

Investments_Additional_Informa

Investments - Additional Information (Detail)	Dec. 31, 2013
Minimum	'
Schedule of Investments	'
Securities maturity length	'5 months
Maximum	'
Schedule of Investments	'
Securities maturity length	'16 months

Information_Regarding_Patents_

Information Regarding Patents and Licenses (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Accumulated Amortization	$11,032	$10,853
Patents and licenses	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Weighted Average Original Life (years)	'18 years 6 months 18 days	'14 years 10 months 17 days
Gross Carrying Amount	13,840	11,690
Accumulated Amortization	$11,032	$10,853

Patents_and_Licenses_Additiona

Patents and Licenses - Additional Information (Detail) (Patents and licenses, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Patents and licenses	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Aggregate amortization expense	$179,000	$162,000	$272,000

Estimated_Future_Amortization_

Estimated Future Amortization Expense (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'
2014	$269
2015	269
2016	269
2017	173
2018	$141

Line_of_Credit_Additional_Info

Line of Credit - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Line of Credit Facility [Line Items]	'
Term loan, maturity period	'2 years
Revolving Credit Facility | Period One	'
Line of Credit Facility [Line Items]	'
Revolving line of credit, LIBOR interest rate assessment period	'30 days
Revolving Credit Facility | Period Two	'
Line of Credit Facility [Line Items]	'
Revolving line of credit, LIBOR interest rate assessment period	'60 days
Revolving Credit Facility | Period Three	'
Line of Credit Facility [Line Items]	'
Revolving line of credit, LIBOR interest rate assessment period	'90 days
Revolving Credit Facility | Before Amendment	'
Line of Credit Facility [Line Items]	'
Revolving line of credit, maximum principal amount	25
Revolving Credit Facility | After Amendment	'
Line of Credit Facility [Line Items]	'
Revolving line of credit, maximum principal amount	40
Revolving Credit Facility | Libor Plus Applicable Margin	'
Line of Credit Facility [Line Items]	'
Revolving line of credit, interest plus LIBOR	1.17%

Income_Tax_Expense_Detail

Income Tax Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Line Items]	'	'	'
Federal income tax, current	$12,541	$8,934	$9,973
State income tax, current	1,065	1,050	880
Income tax, current	13,606	9,984	10,853
Federal income tax, deferred	-1,063	1,363	2,372
State income tax, deferred	140	99	212
Income tax, deferred	-923	1,462	2,584
Total income tax expense	$12,683	$11,446	$13,437

Deferred_Income_Tax_Assets_and

Deferred Income Tax Assets and Liabilities with Temporary Differences and Carryforwards (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Benefit plans	$1,590	$1,099
Inventories	525	536
Other	37	38
Total deferred tax assets	2,152	1,673
Deferred tax liabilities:	'	'
Property, plant and equipment	9,716	10,299
Patents and goodwill	2,956	2,972
Other	166	11
Total deferred tax liabilities	12,838	13,282
Net deferred tax liability	10,686	11,609
Balance Sheet classification:	'	'
Non-current deferred income tax liability	12,062	12,232
Current deferred income tax asset	1,376	623
Net deferred tax liability	$10,686	$11,609

Illustration_of_Total_Income_T

Illustration of Total Income Tax Expense Difference with Amount Provided by Applying Statutory Federal Income Tax Rate to Pretax Earnings (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Provision of Income Taxes [Line Items]	'	'	'
Income tax expense at the statutory federal income tax rate	$13,743	$12,276	$13,816
Increase (decrease) resulting from:	'	'	'
State income taxes	770	747	710
Section 199 manufacturing deduction	-1,307	-949	-996
Other, net	-523	-628	-93
Total income tax expense	$12,683	$11,446	$13,437

Reconciliation_of_Beginning_an

Reconciliation of Beginning and Ending Balances of Total Amounts of Gross Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Contingency [Line Items]	'	'	'
Gross unrecognized tax benefits beginning balance	$541,000	$1,261,000	$1,420,000
Increase in tax positions for prior years	11,000	19,000	'
Decreases in tax positions for prior years	'	'	-77,000
Increase in tax positions for current year	0	0	134,000
Decrease due to settlement with taxing authorities	-641,000	-641,000	'
Lapse in statutes of limitation	-206,000	-98,000	-216,000
Gross unrecognized tax benefits ending balance	$346,000	$541,000	$1,261,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Line Items]	'	'	'
Unrecognized tax benefits, reduced	$641,000	$641,000	'
Allowed percentage by the IRS appeal group for research and development tax credit	100.00%	'	'
Unrecognized tax benefits, accrued interest	21,000	26,000	77,000
Unrecognized tax benefits, net interest benefit	$5,400	$51,000	$7,000

Stockholders_Equity_Additional

Stockholders Equity - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended			12 Months Ended
	Dec. 10, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Aug. 16, 2011
Class of Stock [Line Items]	'	'	'	'	'	'	'	'
Stock repurchase program, shares authorized to be repurchased	'	'	'	'	'	'	'	200,000
Stock repurchase program, number of shares repurchased	'	'	'	'	36,666	26,562	8,000	'
Stock repurchase program, shares remained eligible for repurchase	'	'	'	'	128,772	165,438	'	'
Dividend	$10	$0.64	$0.56	$0.49	'	'	'	'
Non-cash dividends	'	'	'	'	$29,000	$157,000	$30,000	'
Rights Plan, expiration period	'	'	'	'	'2016-08	'	'	'
Executive Officers	'	'	'	'	'	'	'	'
Class of Stock [Line Items]	'	'	'	'	'	'	'	'
Stock repurchase program, number of shares repurchased	'	'	'	'	6,704	'	'	'

Computation_of_Basic_and_Dilut

Computation of Basic and Diluted Income Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of Earnings Per Share, Basic and Diluted, by Common Class	'	'	'	'	'	'	'	'	'	'	'
Net Income	$5,768	$7,673	$6,506	$6,635	$4,894	$7,259	$6,099	$5,377	$26,582	$23,629	$26,038
Weighted Average Basic Shares Outstanding	'	'	'	'	'	'	'	'	2,010	2,016	2,019
Add: Effect of dilutive securities	'	'	'	'	'	'	'	'	7	11	12
Weighted average diluted shares outstanding	'	'	'	'	'	'	'	'	2,017	2,027	2,031
Net Income per share	'	'	'	'	'	'	'	'	'	'	'
Basic	$2.88	$3.82	$3.23	$3.28	$2.42	$3.60	$3.03	$2.67	$13.22	$11.72	$12.90
Diluted	$2.87	$3.81	$3.22	$3.28	$2.42	$3.59	$3.02	$2.65	$13.18	$11.66	$12.82

Income_per_Share_Additional_In

Income per Share - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share	'
Shares Excluded from Computation of Weighted average diluted Shares outstanding	4,344

Stock_Plans_Additional_Informa

Stock Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of stock-based compensation plans	3	'	'
Excess tax benefit from Share-based Compensation	$15,000	$1,412,000	$79,000
Stock compensation plan, weighted average grant date fair value of options granted	$0	$40.38	$40.64
Stock compensation plan, total intrinsic values of options exercised	0	3,100,000	0
Stock compensation plan, total intrinsic values of options outstanding	4,600,000	'	'
Stock compensation plan, total intrinsic values of options exercisable	1,500,000	'	'
Stock-based compensation expense	1,586,000	1,482,000	1,047,000
Stock-based compensation expense, total tax benefit recognized	555,000	516,000	359,000
General and Administrative Expense	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense	1,586,000	1,482,000	1,047,000
Restricted Stock	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation plan, stock awards vested	633,000	559,000	481,000
Stock compensation plan, number of restricted stock units outstanding	10,500	13,500	'
Restricted Stock Units (RSUs)	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation plan, conversion ratio of a restricted stock unit to ordinary shares of stock	1	'	'
Stock compensation plan, restricted stock units conversion period	'5 years	'	'
Stock compensation plan, number of restricted stock units outstanding	12,904	11,996	'
Non Employee Director | Restricted Stock Units (RSUs)	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation plan, stock awards vested	8,000	22,000	8,000
Stock compensation plan, number of restricted stock units outstanding	389	'	'
Stock compensation plan, total intrinsic value of unvested restricted stock	3,938,000	'	'
2006 Equity Incentive Plan	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation plan, number of common stock shares reserved	200,000	'	'
Stock compensation plan, remaining number of common stock shares reserved	58,242	'	'
2006 Equity Incentive Plan | Non Employee Director | Restricted Stock Units (RSUs)	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation plan, stock awards vested	$120,000	$120,000	$120,000
Deferred Compensation Plan | Non Employee Director	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation plan, number of common stock shares reserved	2,500	'	'
Stock compensation plan, remained shares of common stock reserved for issuance	1,626	'	'
Director Stock Purchase Plan | Non Employee Director	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock compensation plan, number of common stock shares reserved	2,500	'	'
Stock compensation plan, remaining number of common stock shares reserved	1,126	'	'

Stock_Option_Transactions_Deta

Stock Option Transactions (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Shares	'
Outstanding at December 31, 2012	50,000
Granted	'
Exercised	'
Outstanding at December 31, 2013	50,000
Exercisable at December 31, 2013	15,000
Weighted Average, Exercise Price	'
Outstanding at December 31, 2012	$204.76
Granted	'
Exercised	'
Outstanding at December 31, 2013	$204.76
Exercisable at December 31, 2013	$196.99
Weighted Average Remaining Contractual Term	'
Outstanding at December 31, 2013	'4 years 10 months 24 days
Exercisable at December 31, 2013	'4 years 8 months 12 days

BlackScholes_Option_Pricing_Mo

Black-Scholes Option Pricing Model Weighted Average Assumptions (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	'	0.50%	1.70%
Dividend yield	'	1.00%	1.00%
Volatility factor	'	25.00%	25.00%
Expected life	'0 years	'5 years	'5 years

Restricted_Stock_Activity_Deta

Restricted Stock Activity (Detail) (Restricted Stock, USD $)	12 Months Ended
	Dec. 31, 2013
Restricted Stock	'
Shares	'
Beginning Balance	13,500
Granted	'
Vested	-3,000
Ending Balance	10,500
Weighted Average Award Date Fair Value Per Share	'
Beginning Balance	$207.35
Granted	'
Vested	$211.06
Ending Balance	$208.09

Changes_in_Stock_Units_Detail

Changes in Stock Units (Detail) (Restricted Stock Units (RSUs), USD $)	12 Months Ended
	Dec. 31, 2013
Stock Units	'
Beginning Balance	11,996
Granted	908
Ending Balance	12,904
Weighted Average Grant Date Fair Value Per Unit	'
Beginning Balance	$194.95
Granted	$214.76
Ending Balance	$196.35
Director's Stock Units	'
Stock Units	'
Granted	41
Vested	-41
Weighted Average Grant Date Fair Value Per Unit	'
Granted	$199.78
Vested	$199.78

Unrecognized_Compensation_Cost

Unrecognized Compensation Cost (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unrecognized Compensation Cost, stock options	1,172,000
Total Unrecognized Compensation Cost	4,339,000
Stock Options	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted Average Remaining Years in Amortization Period	'3 years
Restricted Stock	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unrecognized Compensation Cost, other than options	1,812,000
Weighted Average Remaining Years in Amortization Period	'3 years
Restricted Stock Units (RSUs)	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unrecognized Compensation Cost, other than options	1,355,000
Weighted Average Remaining Years in Amortization Period	'3 years 3 months 18 days

Revenues_from_Major_Customers_

Revenues from Major Customers - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
									Customer	Customer
Concentration Risk [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of major customer	'	'	'	'	'	'	'	'	1	1	'
Net revenues	$31,851	$34,044	$32,605	$33,493	$28,497	$30,637	$30,689	$29,239	$131,993	$119,062	$117,704
Major Customer | Revenue	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	$13,500	$15,100	'
Percentage of net revenue	'	'	'	'	'	'	'	'	10.20%	12.90%	'

Industry_Segment_and_Geographi2

Industry Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Segment	Segment	Segment
Segment Reporting Information [Line Items]	'	'	'
Number of reportable industry segment	1	1	1
Geographic Concentration Risk | Outside United States | Revenue	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Percentage of revenues	42.00%	42.00%	42.00%

Revenues_by_Geographic_Territo

Revenues by Geographic Territory (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$31,851	$34,044	$32,605	$33,493	$28,497	$30,637	$30,689	$29,239	$131,993	$119,062	$117,704
United States	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	75,997	69,388	68,156
Canada	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	15,114	13,352	17,524
Other Countries less than 10% of revenues	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	$40,882	$36,322	$32,024

Revenue_by_Product_Line_Detail

Revenue by Product Line (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$31,851	$34,044	$32,605	$33,493	$28,497	$30,637	$30,689	$29,239	$131,993	$119,062	$117,704
Fluid Delivery	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	51,289	49,060	45,274
Cardiovascular	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	40,182	36,021	34,072
Ophthalmology	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	20,736	15,717	19,581
Other	'	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	$19,786	$18,264	$18,777

Employee_Retirement_and_Benefi1

Employee Retirement and Benefit Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'	'
Defined contribution plan, employer contribution	$561,000	$533,000	$487,000

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Loss Contingencies [Line Items]	'
Gain contingency, potential future payment receivable under settlement	$5.50
Loss contingency, estimated payment from termination of executive officers	$4.30

Quarterly_Financial_Data_Detai

Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Operating Revenue	$31,851	$34,044	$32,605	$33,493	$28,497	$30,637	$30,689	$29,239	$131,993	$119,062	$117,704
Operating Income	8,336	10,713	9,495	9,400	7,039	9,677	8,967	7,943	37,944	33,626	38,168
Net Income	$5,768	$7,673	$6,506	$6,635	$4,894	$7,259	$6,099	$5,377	$26,582	$23,629	$26,038
Income Per Basic Share	$2.88	$3.82	$3.23	$3.28	$2.42	$3.60	$3.03	$2.67	$13.22	$11.72	$12.90
Income Per Diluted Share	$2.87	$3.81	$3.22	$3.28	$2.42	$3.59	$3.02	$2.65	$13.18	$11.66	$12.82

Schedule_II_Consolidated_Valua1

Schedule II - Consolidated Valuation and Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Beginning balance	$47	$42	$36
Additions charged to expense	69	36	40
Deductions from reserve	-29	-31	-23
Recovery	-1	'	-11
Ending balance	$86	$47	$42